# Patrick Baeuerle

> Patrick Baeuerle is a Series A investor at MPM Capital backing Medical. See 2 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: Angel Investor
- Fund: [MPM Capital](https://shizune.co/investors/profile/mpm-capital)
- Location: Cambridge, United States
- Total investments: 2
- Last investment: Mar 2018
- Lead investor: 50%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/in/patrick-a-baeuerle-04266b55

Patrick Baeuerle is a Series A investor at MPM Capital in Cambridge focused on Medical and Health Care. Patrick A. Baeuerle is the Executive Partner of MPM Capital. He previously worked at Amgen Research as a Vice President of Research and General Manager. Patrick A. Baeuerle attended the University of Konstanz and LMU Munich.

## Contacts

5 contacts available for Patrick Baeuerle: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/patrick-baeuerle?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series B | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TCR2 | TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to expressdefined TCR alpha/beta chains.TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world. | $125M | Series B | Mar 21, 2018 | http://www.tcr2.com/ |
| TCR2 | TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to expressdefined TCR alpha/beta chains.TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world. | $44.5M | Series A | Dec 08, 2016 | http://www.tcr2.com/ |

2 of 2 investments shown.

## Co-investors
- [F2 Ventures](https://shizune.co/investors/profile/f2-ventures) — VC Fund, 2 deals together
- [UBS Asset Management](https://shizune.co/investors/profile/ubs-asset-management) — VC Fund, 2 deals together
- [6 Dimensions Capital](https://shizune.co/investors/profile/6-dimensions-capital) — VC Fund, 1 deal together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 1 deal together
- [Cathay Capital](https://shizune.co/investors/profile/cathaycapital) — VC Fund, 1 deal together

## About MPM Capital

VC Fund · Cambridge, United States

MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.

5 contacts available at MPM Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Dan Hicklin | Managing Director | https://shizune.co/investors/profile/dan-hicklin |
| David P. Ryan | Medical and Scientific Advisor | https://shizune.co/investors/profile/david-p-ryan |
| Detlev Biniszkiewicz | Executive Partner | https://shizune.co/investors/profile/detlev-biniszkiewicz |
| Patrick Baeuerle | Excutive Partner | https://shizune.co/investors/profile/patrick-baeuerle |
| Uciane Scarlett | Principal | https://shizune.co/investors/profile/uciane-scarlett |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Patrick Baeuerle invest in?

Patrick Baeuerle invests primarily in Medical, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Patrick Baeuerle?

Public channels for Patrick Baeuerle include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Patrick Baeuerle last invest?

The most recent investment recorded for Patrick Baeuerle closed in Mar 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co